FDA uses Wolters Kluwer Pharma Solutions' prescription data for tracking viral treatments

Wolters Kluwer Pharma Solutions, Inc., a leading provider of market data and competitive intelligence to the pharmaceutical and biotech industries, announced today that the Food and Drug Administration (FDA) is using its prescription data to track the treatment of H1N1 and other influenza viruses. These weekly updates provide the FDA with visibility to clusters of patients across the U.S. being treated with the four most popular oral anti-viral prescriptions.

The data provided will allow officials to see areas of the country where oral anti-virals are being filled and to identify clusters where high concentrations of usage occur. In addition to a breakdown by geography, the data also provide FDA with specific demographic information associated with oral anti-viral patients.

"The FDA is using our prescription data as a means of tracking the treatment of populations affected by flu outbreaks including the H1N1 virus, and the specific medications being used to treat them," said Mark Spiers, President and CEO of Wolters Kluwer Pharma Solutions. "The data are typically not more than five days old upon delivery. This near real-time picture provides the FDA an ability to act quickly in the event of a public health crisis."

The updates provide detailed breakdowns for each of the four anti-virals including the ability to track nationally, regionally, and at the state, core based statistical area (CBSA) and combined statistical area (CSA) levels. The contract calls for Wolters Kluwer Pharma Solutions to provide two years' prescribing data for each drug to help FDA see historical norms of usage. This makes it possible for FDA to identify spikes in prescriptions used to treat flu and the H1N1 virus.

The weekly flu tracking commenced in early September and will continue for one year at a minimum.

"We've already been successful at identifying clusters of anti-viral prescriptions in various geographic pockets," said Joe Markmann, Director for Healthcare Policy, Wolters Kluwer Pharma Solutions. "One of them recently shows clear spikes within regions of Alabama, a finding that reflects what the CDC is reporting and further reinforces the reliability of the data."

To deliver the data, Wolters Kluwer Pharma Solutions utilizes two of its most powerful data-analytics tools. The first is Source Lx Patient Studies Suite for capturing patient-level data, which describe prescription drug use by patient demography. For the required prescription-level data, the company uses Pharmaceutical Audit Suite (PHAST), which captures 80% of the prescription transactions in the U.S., the greatest prescription coverage in the industry.

Last November, Wolters Kluwer Pharma Solutions was one of three awardees for a multi-year contract to provide both prescription and patient-level data to the FDA to give insight into the prevalence of prescription drug utilization within the U.S. population. Weekly flu tracker is an add-on assignment to that program.